Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.07), $0.02 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $28.9 million versus the consensus estimate of $4 million.

For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.